

117TH CONGRESS
2D SESSION

H. RES. 1287

Of inquiry directing the President to provide certain documents in the President's possession to the House of Representatives relating to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain.

IN THE HOUSE OF REPRESENTATIVES

JULY 26, 2022

Mr. WALBERG submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Of inquiry directing the President to provide certain documents in the President's possession to the House of Representatives relating to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain.

1 *Resolved*, That not later than 14 days after the adop-
2 tion of this resolution, the President is directed to furnish
3 to the House of Representatives copies of any document
4 or record, audio recording, memorandum, call log, cor-
5 respondence (electronic or otherwise), or other commu-
6 nication in the President's possession (or any portion
7 thereof), that refers or relates to the following:

1 (1) the memoranda and report referenced in the
2 testimony given by Dr. Robert Califf on May 25,
3 2022, during the hearing related to the recall of in-
4 fant formula manufactured by Abbott Laboratories
5 and potential impacts on the infant formula supply
6 chain held by the Committee on Subcommittee on
7 Oversight and Investigations of the Committee on
8 Energy and Commerce of the House of Representa-
9 tives;

10 (2) all communications between the Commis-
11 sioner of Food and Drugs and other staff of the
12 Food and Drug Administration and the White
13 House regarding the infant formula recall and po-
14 tential impact during or before February 2022;

15 (3) the failure of the Food and Drug Adminis-
16 tration to ensure the whistleblower complaint sub-
17 mitted to the Food and Drug Administration by an
18 employee of Abbott Laboratories was sent to all nec-
19 essary and appropriate officials and what actions the
20 Food and Drug Administration has taken to prevent
21 such a failure from happening in the future;

22 (4) the number of full-time equivalent positions
23 in the Office of Regulatory Affairs of the Food and
24 Drug Administration that remain vacant for food
25 safety compliance and inspection staff;

1 (5) all communications between the Food and
2 Drug Administration and the Department of Agri-
3 culture about the recall of infant formula manufac-
4 tured by Abbott Laboratories and the potential im-
5 pact on the Special Supplemental Nutrition Program
6 for Women, Infants, and Children, including the
7 timing of such communications; and

8 (6) the number of submissions pending at the
9 Food and Drug Administration as of the date of the
10 adoption of this resolution for the marketing of in-
11 fant formula, delineated by domestic and foreign
12 manufacturers.

○